Gammaproteobacteria correlate with low PD-L1 expression and poor patient survival under ICI therapy. (a) Comparative analysis of Gammaproteobacteria abundance in healthy lung and NSCLC samples. (b-e) Analysis of Gammaproteobacteria abundance in stratified subgroups of NSCLC patients. (f-i) Analysis of Gammaproteobacteria abundance in terms of PD-L1 expression, ICI treatment responsiveness, and patient survival. (a-g) Boxes indicate the median (highlighted in bold) and interquartile ranges. Whiskers indicate the minimum and maximum values except in the case of outliers (outliers are indicated by circles and extreme outliers are indicated by stars). (H + I) cutoffs used for Gammaproteobacteria stratification: 480 for PFS and 811 for OS
ADC, adenocarcinoma; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SCC, squamous cell carcinoma; SD, stable disease.